[Minutes, Advisory Committee to the Director GP-160 Meeting (1992: Bethesda, Maryland)]

24

1 date.
2 The immunogens involve either the gp-160
3 or the gp-120 sequence of the envelope, produced in
4 either insect cells or a variety of other cells,
5 especially the mammalian cells which are thought to
6 produce a more natural glycocelation.
7 The HIV -- one strain of the immunogen is,
8 in the earliest experiments, the LAI or 3B, and more
9 recently products are moving to the MN or SF2 strains,
10 which are more prevalent, at least in the developed
11 world, using a variety of adjuncts. Next slide.
12 Here we see a list of others. This list
13 is probably not exhaustive, but at least several other
14 candidates that we are aware of in seropositives. The
15 CORE -- the HIV CORE protein from the group in
16 Britain, a synthetic peptide of immunodominant
17 peptides being developed at the group at Duke, soon to
18 enter clinical trial.
19 The only one in this group to have
20 significant data reported to date is a whole and
21 activated virus. It's an envelope depleted vaccine
22 from the Immune Response Corporation pioneered by Dr.
NEAL R. GROSS
COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVENUE, N.W.
(202) 234- 4433 WASHINGTON, D.C. 20005 (202) 234- 4433